EWING, N.J., March 13 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company) announced today that it has appointed Brian L. Hamilton, MD, PhD, as Senior Vice President and Chief Medical Officer. Dr. Hamilton is a recognized expert in both the global development of topically active steroids as well as in Graft-versus-Host disease (GVHD) and has had a long and distinguished career of more than 25 years in both academia and industry, most notably at Wyeth and Astra, USA. Dr. Hamilton will lead DOR's clinical affairs, with an emphasis on the execution of its confirmatory Phase 3 clinical trial of orBec(R) (oral beclomethasone dipropionate or BDP) in the treatment of acute GI GVHD.
Dr. Hamilton earned his MD and PhD (Transplantation Immunology) at the University of Washington, Seattle, and trained in Pediatrics, Allergy/Immunology, and Oncology. He began his training in bone marrow transplantation while in medical school, with further training at the Children's Hospital Medical Center, Boston, MA. His academic career, at the University of Washington and the University of Miami, focused on pediatric immunology and bone marrow transplantation. His research focus was in the immunobiology of GVHD in an animal model. He also spent several years as Chief of Immunology at the Children's Hospital, Oakland, CA with a clinical appointment on the Pediatric Bone Marrow Transplant Service at the University of California - San Francisco.
Following his academic career, Dr. Hamilton joined the pharmaceutical industry, initially at Astra, USA in Westborough, MA working on inhaled steroids (Rhinocort Aqua and Pulmicort Turbuhaler) for the treatment of allergic rhinitis and asthma, including three successful new drug applications for these products. He has worked with several pharmaceutical and biotechnology companies including Alkermes in multiple therapeutiPage: 1 2 3 4 5 Related biology technology :1
. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results2
. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC3
. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT4
. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 20095
. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 20086
. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification7
. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells8
. Eiger BioPharmaceuticals Raises $7.1 Million A Round9
. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss10
. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm11
. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical